Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: J Pineal Res. 2016 Aug 19;61(3):396–407. doi: 10.1111/jpi.12358

Fig. 3.

Fig. 3

Analysis of membrane polarization status, oxidative stress and cell death in Hep3B under sorafenib and melatonin treatment. ROS production by DCF quantification and mitochondrial membrane potential by JC-1 determination were evaluated in Hep3B cells incubated with sorafenib (2.5μM), melatonin (1 and 2 mM) and the combination of both compounds at different times. (B) Flow cytometric assessment of cell viability was performed using an Annexin V–propidium iodide kit after 48 hours of treatment. (C). Representative immunoblots of PARP and BAX in Hep3B cells incubated with sorafenib (2.5μM) alone and combined with melatonin (1mM) at different times. (D) Images of immunoblots are representative for experiments performed in triplicate. Data are expressed as a percentage of mean values ± S.E.M. of three independent experiments. *p < 0.05 versus control cells.